GE EK-Pro Arrhythmia Algorithm
Transcription
GE EK-Pro Arrhythmia Algorithm
GE Healthcare Quick Guide GE EK-Pro Arrhythmia Algorithm Multi-lead arrhythmia monitoring Arrhythmia means any disturbance or irregularity of the cardiac rhythm. Stability of the cardiac rhythm is essential for sufficient pumping function of the heart and adequate cardiac output. Maintaining adequate cardiac output is vital for organ perfusion and survival. Therefore, fast and accurate detection of arrhythmia is critical. Each ECG lead views the heart at a unique angle. Multi-lead monitoring provides continuous viewing of the heart rhythm from multiple sites. The more leads that are used, in general, the more reliable the information is for arrhythmia analysis. The recognition of ventricular beats may be improved by multi-lead monitoring, and the same applies to QRS detection. The decision between normal and ventricular beats may be more reliable when information from more than one lead is available. The GE EK-Pro arrhythmia algorithm uses I, II, III, and the V/VA lead for arrhythmia detection. The American Heart Association (AHA) has recommended that two or preferably three or more leads should be displayed and monitored simultaneously. Exceeding the AHA’s minimum recommendation, the distinctive GE EK-Pro algorithm utilizes four simultaneous leads for analysis. A multi-lead arrhythmia algorithm uses more than one ECG lead for detection and analysis of cardiac arrhythmias. The performance of a multi-lead algorithm, in general, may exceed that of a single-lead algorithm. In noisy situations, there might be noise present on some leads, while the signal in other leads might be good enough for reliable detection of cardiac rhythm. Sometimes ventricular beats can be more obvious in some of the leads than in others where the changes in morphology are minor. It is also possible that QRS amplitude can be low in one lead and normal in others. Therefore, the sensitivity of the algorithm may increase when more than one lead is used. Window in CARESCAPE modular monitors to select the ECG leads to be analysed. EK-Pro_DOC0783131.indd 1 11.11.2010 15.24 How are arrhythmias monitored? The GE EK-Pro algorithm processing can be represented by three major phases: 1) Event Detection and Correlation, 2) Event Measurement and Classification, and 3) Arrhythmia Detection. Continuous correlation, incremental template updating and contextual analysis are processing techniques used by the GE EK-Pro algorithm. Continuous correlation attempts to find the best match between each incoming complex and the set of stored (learned) templates. Incremental template updating allows information from each beat, which correlates over time, to be reflected in the associated template. Contextual analysis uses information from neighboring QRS complexes along with existing template measurements to make the best possible decision regarding the beat’s origin (e.g., early, wide). Additionally, the GE EK-Pro algorithm also monitors ST changes of up to 12 leads. For ST monitoring details, please consult the appropriate user manual. Event Detection and Correlation filters the incoming signal before detecting the incoming events. As the events are detected, incremental template updating is applied on the signal. Here also the noise analysis is done in order to decide whether if any of the incoming channels are too noisy to be analyzed. Each detected QRS complex is compared to previously detected QRS complexes and the templates are updated accordingly, or a new template is created and the beat is added on the beat list. Practical aspects in bedside arrhythmia monitoring Signal quality Careful skin preparation and the use of high-quality electrodes are key to ensuring a good signal in ECG and especially arrhythmia monitoring. A good signal helps ensure accurate arrhythmia detection and helps decrease the number of false alarms. In case there is an artifact in one of the analyzed leads, the GE EK-Pro algorithm gives a message on noisy ECG and, if the condition continues, the algorithm finally goes into suspend mode. This is communicated by “Arrhyhtmia paused” or “Arrhy suspend” message, depending on the GE monitor in use. Artifacts can be a result of motion or poor skin-electrode contact. Relearning When the morphology of the patient’s ECG changes considerably (e.g. due to change of electrodes/electode locations), relearning should be started manually. This can be done in the ECG menu by selecting Relearn QRS. Patients with pacemakers Pacemaker detection needs to be activated when patients with pacemakers are monitored. Pacemaker detection is always on with the E-PSM or E-PRESTN module family. Pacemaker detection needs to be activated when the CARESCAPE™ Patient Data Module or Tram™ is used. Event Measurement and Classification task uses the beat list to define the timing, for example, the temporal information of the patient rhythm. The algorithm can classify the beat in question by using the information from the preceding and following beats. A beat is classified as normal, ventricular or artifact and, in combination of the decision of the past beat template, the final label is given and the heart rate is also updated accordingly. Arrhythmia Detection uses the beat list to get information in run lengths of normal and ventricular beats. Based on this, R-R interval information and heart rate, the algorithm concludes whether there are any arrhythmias present. The criteria for calling an arrhythmia are listed in the table at the end of this document. There is a separate analysis to detect the presence of ventricular fibrillation. The Advanced ECG tab provides the user with options to adjust the ECG settings. Examples of options include Pacemaker Detection, Relearning QRS, and switching between multi-lead and single lead analysis. EK-Pro_DOC0783131.indd 2 11.11.2010 15.24 Bedside arrhythmia alarms In GE monitors there are two arrhythmia analysis modes: Lethal and Full. The Lethal mode is the standard and Full is an optional choice. The Lethal mode detects asystole, ventricular fibrillation/ventricular tachycardia and ventricular tachycardia. In the neonatal mode bradycardia is also considered a lethal arrhythmia. The details of arrhythmia alarms criteria are described in the following table. A Fib, Irregular (Tram) Absence of P-waves and irregular R-R intervals Accel. Ventric. Run of PVCs with a run length of at least six beats and the rate requirements have not met V Tach or V Brady Asystole HR decreased to zero Bigeminy Every other beat is a PVC (N-V-N-V-N) Couplet Two consecutive PVCs are detected between normal beats N-V-V-N. The coupling interval between the PVCs must be less than 600ms HR High/Tachy, PSM: HR High only The displayed 4/8-beat average ECG heart rate exceeds the user-selected common HR high limit or ECG HR high limit HR Low/Brady The displayed 4/8-beat average ECG heart rate falls below the user-selected common HR low limit or ECG HR low limit Missing Beat* Actual R-R interval more than 1.8 times the average R-R interval Multifocal PVCs* Over the last 15 beats two or more premature ventricular beats with different morphologies are detected Pause Actual R-R interval exceeds 3s (Tram) or a configured value 1-5s (CARESCAPE Patient Data Module) CARESCAPE Patient Data Module, Tram: V Fib/V Tach ECG waveform indicates a chaotic ventricular rhythm R on T Isolated PVC is detected within 100 ms of the peak of the T-wave of the patient’s predominant normal beat Rapid VT* A run on PVCs is detected with a run length of six beats or more. In addition, an effective heart rate that exceeds 160 bpm Single PVC An isolated PVC is detected Trigeminy Every third beat is a PVC (N-N-V-N-N-V-N) V Brady Run of PVCs with a run length of at least three beats; additionally, at least two consecutive R-R intervals in the run must have an effective HR less than the age specific limits (60 or 50) V Tach A run of PVCs, with run length six beats or more; in addition, an effective HR that exceeds 100 - 160 beats per minute (age-specific limits) VT > 2 A run of PVCs, with run length more than two beats, but less than six, and less than required for V Tach; additionally, at least two concecutive R-R intervals must have an effective HR that exceeds 100-160 beats per minute (age specific limits) The GE EK-Pro algorithm is used with the CARESCAPE Patient Data Module, CARESCAPE Monitor B850, CARESCAPE Monitor B650, Tram module, Solar® monitors, Dash® monitors, ApexPro® telemetry, and CARESCAPE Telemetry. * Missing beat, Multifocal PVC and Rapid VT alarm labels are only available with version 12 of the GE EK-Pro arrhythmia algorithm. Version 12 is only available with the CARESCAPE Monitor B650 when used with the Patient Side Module (E-PSM). In case of these alarms CARESCAPE Monitor B650 sends mapped alarms to the CARESCAPE Network. This is due to limitations in the CARESCAPE Network. Alarms are mapped as follows: Missing beat sent as Pause, Multifocal PVC sent as PVC, Rapid VT sent as V Tach. For the most current arrhythmia calls, please consult the user manual specific to your current monitor for the details. Additional resources For white papers, guides and other instructive materials about our clinical measurements, technologies and applications, please visit http://clinicalview.gehealthcare.com/ EK-Pro_DOC0783131.indd 3 11.11.2010 15.24 © 2010 General Electric Company – All rights reserved. GE, GE Monogram, CARESCAPE and ApexPro are trademarks of General Electric Company. Solar, Dash and Tram are trademarks of GE Medical Systems Information Technologies, Inc. GE Healthcare reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your GE Healthcare representative for the most current information. GE Healthcare Finland Oy, a General Electric company, doing business as GE Healthcare. GE Healthcare, a division of General Electric Company. CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed medical practitioner. Consult the monitor User’s Guide for detailed instructions. About GE Healthcare GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com. GE Healthcare 8200 West Tower Avenue Milwaukee, WI 53223 U.S.A. GE Healthcare Finland Oy Kuortaneenkatu 2 00510 Helsinki Finland www.gehealthcare.com GE Healthcare 3/F Building # 1, GE Technology Park 1 Hua Tuo Road Shanghai 201203 China imagination at work DOC0783131 10/10 EK-Pro_DOC0783131.indd 4 11.11.2010 15.24